Following on from "All matrixs` are derived from animal or human tissue and have issues."
Regenix is a company that is trying to do pretty much what Polynovo is doing with a matrix derived from human cadaver skin. They have recently received approval to start a clincal trial which seems to be similar to Polynovos` BTM trial.
The outlook is worth a read and sets out some problems that the Polynovo matrix dosen`t have namely excessive cost and shortages of tissue.
"We continue to build a comprehensive body of data to support the validity of dCELL® technology's effectiveness in treating various conditions. Furthermore, we believe that regenerative medicine is capable of revolutionising healthcare and significantly improving patient outcomes.
In addition, there are significant cost pressures on healthcare budgets around the world and the delivery of dCELL® solutions will make a significant and beneficial impact. For example the dCELL® Dermis product is aimed at tackling chronic wounds which it is estimated cost the UK alone over £1 billion every year.
The need for products employing tissue engineering is very large and growing quickly. The chronic shortage of human donor tissue will result in even more demand for animal tissue-based solutions. Our pipeline of products remains strong and continues to progress through the various demanding regulatory requirements and is moving towards commercialisation of the leading products in the coming year.
We continue to pursue our objective to become a global leader in our chosen field and are confident we will thereby create significant shareholder value."
Tissue Regenix is capped at about $100mAU with $40mAU in the bank. No product sales as yet. Considering that Polynovo are more advanced in our BTM trial with one trial completed there would seem to be qhite a bit of upside to have in the sp.
CZD Price at posting:
8.3¢ Sentiment: Buy Disclosure: Held
